Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer

[1]  A. El-Sohemy,et al.  High Coffee Intake, but Not Caffeine, is Associated with Reduced Estrogen Receptor Negative and Postmenopausal Breast Cancer Risk with No Effect Modification by CYP1A2 Genotype , 2013, Nutrition and cancer.

[2]  C. Ingvar,et al.  Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status , 2013, Cancer Causes & Control.

[3]  Kishore R. Sakharkar,et al.  Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer , 2013, PPAR research.

[4]  Kishore R. Sakharkar,et al.  Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology , 2013, Journal of drug targeting.

[5]  Zhihua Liu,et al.  Peroxisome Proliferator-activated Receptor γ Agonists Induce Cell Cycle Arrest through Transcriptional Regulation of Krüppel-like Factor 4 (KLF4)* , 2012, The Journal of Biological Chemistry.

[6]  G. Barrera.  Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy , 2012, ISRN oncology.

[7]  L. Galluzzi,et al.  Mitochondrial Control of Cellular Life, Stress, and Death , 2012, Circulation research.

[8]  Lihua Lai,et al.  Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. , 2012, International journal of molecular medicine.

[9]  A. Wolk,et al.  Coffee and black tea consumption and breast cancer mortality in a cohort of Swedish women , 2012, British Journal of Cancer.

[10]  N. Santanam,et al.  Nutraceuticals as Ligands of PPARγ , 2012, PPAR research.

[11]  H. Dvorak,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[12]  T. Nishikawa,et al.  Benzene Metabolite 1,2,4-Benzenetriol Induces Halogenated DNA and Tyrosines Representing Halogenative Stress in the HL-60 Human Myeloid Cell Line , 2011, Environmental health perspectives.

[13]  P. Riccio.  The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. , 2011, Complementary therapies in medicine.

[14]  Jingmei Li,et al.  Coffee consumption modifies risk of estrogen-receptor negative breast cancer , 2011, Breast Cancer Research.

[15]  V. Wong,et al.  Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case–control study , 2010, Journal of Epidemiology & Community Health.

[16]  C. Mammucari,et al.  Signaling pathways in mitochondrial dysfunction and aging , 2010, Mechanisms of Ageing and Development.

[17]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[18]  Chun-ling Wang,et al.  Surfactin induces apoptosis in human breast cancer MCF-7 cells through a ROS/JNK-mediated mitochondrial/caspase pathway. , 2010, Chemico-biological interactions.

[19]  J. Vanamala,et al.  Trigonelline is a novel phytoestrogen in coffee beans. , 2009, The Journal of nutrition.

[20]  S. Fuqua,et al.  Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. , 2009, The American journal of pathology.

[21]  Patrick Wincker,et al.  Generation and analysis of a 29,745 unique Expressed Sequence Tags from the Pacific oyster (Crassostrea gigas) assembled into a publicly accessible database: the GigasDatabase , 2009, BMC Genomics.

[22]  E. Giovannucci,et al.  Coffee consumption and risk of colorectal cancer: A systematic review and meta‐analysis of prospective cohort studies , 2009, International journal of cancer.

[23]  Bin Wang,et al.  Coffee consumption and risk of breast cancer: a metaanalysis. , 2009, American journal of obstetrics and gynecology.

[24]  Scott A. Busby,et al.  Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.

[25]  C. la Vecchia,et al.  Coffee drinking and hepatocellular carcinoma risk: A meta‐analysis , 2007, Hepatology.

[26]  S. Larsson,et al.  Coffee consumption and risk of liver cancer: a meta-analysis. , 2007, Gastroenterology.

[27]  C. Catapano,et al.  Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor-δ Activation in Ovarian Cancer Cells , 2006 .

[28]  G. Muscat,et al.  Orphan nuclear receptors: therapeutic opportunities in skeletal muscle. , 2006, American journal of physiology. Cell physiology.

[29]  B. Frei,et al.  Coffee and Health: A Review of Recent Human Research , 2006, Critical reviews in food science and nutrition.

[30]  Satoshi Yasuda,et al.  Different Residues Mediate Recognition of 1-O-Oleyllysophosphatidic Acid and Rosiglitazone in the Ligand Binding Domain of Peroxisome Proliferator-activated Receptor γ* , 2006, Journal of Biological Chemistry.

[31]  S. Haldar,et al.  Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. , 2005, Carcinogenesis.

[32]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[33]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators , 2004 .

[34]  Salil K. Das,et al.  Expression of Mn-Superoxide Dismutase Gene in Nontumorigenic and Tumorigenic Human Mammary Epithelial Cells , 2004, Journal of biomedicine & biotechnology.

[35]  J. Haddad.  Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. , 2004, International immunopharmacology.

[36]  Peng Huang,et al.  ROS stress in cancer cells and therapeutic implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  Y. Yatabe,et al.  The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. , 2003, Lung cancer.

[38]  Peng Huang,et al.  Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications , 2003, Leukemia.

[39]  E. Burgermeister,et al.  Peroxisome proliferator-activated receptor-γ upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells , 2003, Oncogene.

[40]  J. Koutcher,et al.  ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. , 2000, Cancer research.

[41]  G. Williamson,et al.  Dietary intake and bioavailability of polyphenols. , 2000, The Journal of nutrition.

[42]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[43]  R. Breyer,et al.  Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death , 1999 .

[44]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[45]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[46]  N. Benowitz,et al.  Caffeine and coffee: effects on health and cardiovascular disease. , 1994, Comparative biochemistry and physiology. Part C, Pharmacology, toxicology & endocrinology.

[47]  C. Welsch,et al.  Caffeine (1,3,7‐trimethylxanthine), a temperate promoter of DMBA‐induced rat mammary gland carcinogenesis , 1983, International journal of cancer.

[48]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[49]  Y. Li,et al.  Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375 , 2006, Medical oncology.

[50]  C. Catapano,et al.  Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. , 2006, Neoplasia.

[51]  Philippe Vielh,et al.  Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. , 2004, Cancer treatment reviews.

[52]  E. Burgermeister,et al.  Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. , 2003, Oncogene.

[53]  R. Breyer,et al.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. , 1999, Neoplasia.

[54]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.